

Certification of Mailing or Facsimile Transmission
 I hereby certify that I have reasonable basis to expect that, on the date shown below, this correspondence is being submitted as indicated below:
 [X] mailed or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450
 [] facsimile transmitted to the U.S. Patent and Trademark Office via fax number (703) 872-6706

James F. McBride
 Name _____
 Registration No (if applicable) 1784
 Signature _____
 Date February 17, 2005

IFW



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. : 10/716,297
 Applicant(s) : Bettiol et al.
 Filed : November 18, 2003
 Title : AMINE REACTION COMPOUNDS COMPRISING
 ONE OR MORE ACTIVE INGREDIENTS
 TC/A.U. : 1751
 Examiner : John Hardee
 Conf. No. : 6900
 Docket No. : CM1924MCC
 Customer No. : 27752

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
 P. O. Box 1450
 Alexandria, VA 22313-1450

02/23/2005 MWOLDGE1 00000024 162480 10716297
 01 FC:1806 180.00 DA

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, record is being made on the attached Form PTO/SB08 of documents which the Patent Office may wish to consider in connection with examination of the above-identified patent application. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case. As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 C.F.R. §1.97(h), this Information Disclosure Statement does not constitute an admission of any kind, and specifically is not an admission that the documents listed on attached form PTO/SB08 are, or are considered to be, material to the patentability of the above-identified patent application, as defined in 37 C.F.R. §1.56(b).

1. ☐ 37 C.F.R. §1.97(b)(1) - U.S. Direct (use when filing IDS with nonprovisional patent application, or with Request for Continued Examination (RCE); or within 3 months of filing a nonprovisional patent application)

This information disclosure statement, submitted under 37 C.F.R. §1.97(b)(1), is being filed with the patent application, with a Request for Continued Examination or within three months of the filing date of a national application. Therefore, no fee is believed to be due.

2. ☐ **37 C.F.R. §1.97(b)(3) - (use when filing IDS more than 3 months after filing a nonprovisional patent application, but prior to receipt of first Office Action)**

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(3). An Office Action on the merits in the present application has not yet been received. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

3. ☐ **37 C.F.R. §1.97(b)(4) - (use when filing IDS prior to receipt of first Office Action after the filing of a Request for Continued Examination (RCE) under §1.114)**

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(4). A first Office Action after filing a Request For Continued Examination (RCE) has not yet been received. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

4. ☒ **37 C.F.R. §1.97(c) with fee payment - (use when filing IDS after receipt of first Office Action, and before receipt of Final Office Action, Notice of Allowance, or an action that otherwise closes prosecution)**

This information disclosure statement is being submitted under 37 C.F.R. §1.97(c). A final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in the application (e.g., *Ex parte Quayle*) has not been received as of the date of this submission. I hereby elect to pay the fee set forth in 37 C.F.R. §1.17(p). Please charge the fee set forth in 37 C.F.R. §1.17(p) to Deposit Account Number 16-2480 in the name of The Procter & Gamble Company. A duplicate copy of this letter (or a fee transmittal form) is enclosed to facilitate the charging of the fee.

ADDITIONAL ITEMS TO BE NOTED BY THE EXAMINER:

☐ In accordance with 37 C.F.R. §1.98(a)(2), copies of only foreign patent documents and non-patent literature are enclosed.

OR

☐ (3) All of the cited references were previously cited by or submitted to the USPTO in prior application Case No. ____, U.S. Patent Application Serial No. __, filed __. Priority is claimed to said application under 35 U.S.C. §120. Accordingly, copies of previously submitted references are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d). It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case.

OR

☒ (4) Copies of all said documents, except Cite Numbers 15 thru 27, were submitted and considered in parent application U.S. Patent Application Serial No. 10,310,247, filed December 5, 2002. Priority is claimed to said application under 35 U.S.C. §120. Accordingly, copies of previously submitted references are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d). Copies of references not previously submitted are enclosed. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case.

☐ (5) Pursuant to 37 C.F.R. §1.98(c), a concise explanation of the relevance of each cited reference that is not in the English language is provided.

☒ (6) It is respectfully requested that the Examiner consider and make of record the co-pending applications listed on the attached page.

☐ Additional information is attached.

Respectfully submitted,

THE PROCTER & GAMBLE COMPANY

Signature

James F. McBride

Typed or printed name

Registration No. 43,784

(513) 627-0079

Date: February 17, 2005

Customer No. 27752

(IDS.doc) (Last Revised 1/31/2005)

CO-PENDING U.S. APPLICATIONS

Entire copies of all co-pending applications (or the portion of the application and claims that caused it to be cited) are only required where the cited pending application is NOT stored in the USPTO's IFW system (see 37 CFR 1.98(a)(2)(iii)).

<u>Atty. Docket No.</u>	<u>Serial Number</u>	<u>Inventor(s)</u>	<u>Filing Date</u>	<u>Copy in IFW?</u>
CM1856M2DCC	10/911,283	Bettiol	08/04/2004	
CM1925MCC	10/911,115	Bettiol	08/04/2004	
CM2174M	10/019,179	Besselievre	06/23/2000	
AA439	10/129,676	Saini	11/09/1999	
8757MC	10/978,938	Dykstra	11/01/2004	

[Only applications that remain pending at the time of submitting **this IDS** should be listed here. For applications that have published or issued as patents, the published applications or granted patents should be listed on Form PTO/SB08.]

Please type a plus sign (+) inside this box → [+]

PTO/SB08A/B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Institute for form 1449A/PTO

COMPLETE IF KNOWN

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(use as many sheets as necessary)

Application Number	10/716,297
Confirmation Number	6900
Filing Date	November 18, 2003
First Named Inventor	Jean-Luc Phillippe Bettiol
Group Art Unit	1751
Examiner Name	John Hardee
Attorney Docket Number	CM1924MCC

SHEET 1 of 2

U. S. PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	DOCUMENT NUMBER Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1	US-3,625,710	12/07/1971	Rizzi	
	2	US-4,853,369	08/01/1989	Mookherjee et al.	
	3	US-5,188,753	02/23/1993	Schmidt et al.	
	4	US-5,270,379	12/14/1993	McAndrew et al.	
	5	US-H1468	08/01/1995	Costa	
	6	US-5,086,111	02/04/1992	Pinschmidt Jr. et al.	
	7	US-5,185,083	02/09/1993	Smigo et al.	
	8	US-5,232,553-	08/03/1993	Smigo et al.	
	9	US-5,649,979 equivalent of WO 95/04809	07/22/1997	Pagel et al.	
	10	US-6,103,678	08/15/2000	Masschelein et al.	
	11	US-6,413,920 B1	07/02/2002	Bettiol et al.	
	12	US-6,566,312 B2	05/20/2003	Bettiol et al.	
	13	US-6,511,948 B1	01/28/2003	Bettiol et al.	
	14	US-6,451,751 B1	09/17/2002	Busch et al.	
	15	US-6,790,815 B1	09/14/2004	Bettiol et al.	
	16	US-2003/0211963 A1	11/13/2003	Bettiol et al.	
	17	US-2004/0116320 A1	06/17/2004	Bettiol et al.	
	18	US-6,699,823 B2	03/02/2004	Bettiol et al.	
	19	US-6,764,986 B1	07/20/2004	Busch et al.	
	20	US-6,740,713 B1	05/25/2004	Busch et al.	
	21	US-2003/0228992 A1	12/11/2003	Smets et al.	
	22	US-2004/0097397 A1	05/20/2004	Mohr et al.	
	23	US-2004/0018955 A1	01/29/2004	Wevers et al.	
	24	US-2003/0171250 A1	09/11/2003	Smets et al.	
	25	US-2003/0153473 A1	08/14/2003	McRitchie et al.	
	26	US-2003/0134772 A1	07/17/2003	Dykstra et al.	
	27	US-2003/0158079 A1	08/21/2003	Dykstra et al.	
	28	US-4,640,788	02/03/1987	Kapuscinski et al.	
	29	US-4,187,256	02/05/1980	Giffin et al.	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	FOREIGN PATENT DOCUMENT Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ⁶
	30	GB 1068712 equivalent of DE 17 95 617 attached	03/03/1972	Unilever		
	31	EP 011,499 B1	11/04/1981	Unilever		
	32	EP 175,871 A1	04/02/1986	Ferminich		
	33	EP 392,619 A2	10/17/1990	Quest Int.		
	34	EP 831,143 A1	03/25/1998	Heinsman		
	35	EP 841,391 A1	05/13/1998	Masschelein		
	36	JP 09040687 A2	02/10/1997	Matsumoto		X
	37	WO 93/19787 A1	10/14/1993	Green		
	38	WO 95/08976 A1	04/06/1995	Uson		
	39	WO 96/38528 (publication EP application 95303762.9)	12/05/1996	Hardy		

	40	WO 01/51599 A1	07/19/2001	Wevers		
	41	WO 00/00580 A1	01/06/2000	Japikse		
	42	EP 0 971 025 A1	01/12/2000	Bettiol		
	43	WO 00/02991 A1	01/20/2000	Bettiol		
	44	EP 0 971 024 A1	01/12/2000	Bettiol		
	45	WO 00/02981 A2	01/20/2000	Procter & Gamble		
	46	EP 0 971 026 A1	01/12/2000	Bettiol		
	47	WO 00/02982 A2	01/20/2000	Procter & Gamble		

NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ⁶
	48	Kamogawa et al., <u>Chemical Release Control – Schiff Baes of Perfume Aldehydes and Aminostyrenes</u> , Journal of Polymer Science: Polymer Chemistry Edition, Vol. 20, 1982, pp 3121-3129	
	49	Viguera et al., <u>A Water-Soluble Polylysine-Retinaldehyde Schiff Base Stability in Aqueous and Nonaqueous Environments</u> , Journal of Biological Chemistry, Vol. 265, No. 5, 2/15/90 pp 2527-2532 (XP002057413/ISSN: 0021-9258)	
EXAMINER			DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.